The promise of Eli Lilly's weight-loss drug for sleep apnea adds reasons to own it
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…
Jim Cramer
We're buying more shares of this healthcare company amid an overblown sell-off
Shortly after the opening bell, we will purchase 140 shares of Abbott Laboratories at approximately $112. Following the deal, Jim…
Nvidia tramples the bears. Jim Cramer on struggling stocks Starbucks and Abbott
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Jim Cramer defends Elon Musk's use of ketamine for depression
CNBC's Jim Cramer said Tuesday that Elon Musk's revelation that he takes prescription ketamine for depression was brave and “saved…
Disney scores a victory in the Nelson Peltz board fight. 2 other portfolio stocks recover
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
It's not too late to buy Abbott stock after Friday's sell-off
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
News Coming to GE Healthcare (GEHC) Eliminates Excess Stock
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Here's Eli Lilly's Competitive Advantage in GLP-1 Obesity Drugs and Abbott's Supporting Role
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
TJX quarter delivers and what Cramer expects to hear from Salesforce
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Buy This Vertiv Data Center Company Despite Its Weak Guidance
Vertiv Holdings: The data center equipment maker, whose stock has roughly quadrupled over the past year, issued guidance that fell…